Amrita Krishnan, M.D.

Newport Beach
Newport Beach, CA 92660
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
1990, Albany Medical College, Albany, NY, M.D., Medicine
1988, Union College, Schenectady, NY, B.S., Biology/Modern Languages
1996 - 1997, Clinical Fellow, Bone Marrow Transplantation City of Hope
1993 - 1996, Clinical Fellow, Hematology-oncology Beth Israel Hospital, Harvard University Boston MA
1993 - 1996, Clinical Fellow Clinical Fellow in Medicine, Harvard Medical School Boston MA
1995 - 1996, Research Fellow Division of Hematologic Malignancies, Principal Investigator, J. Ritz Dana Farber Cancer Institute Harvard University, Boston MA
1995, Clinical Fellow, Bone Marrow Transplantation Fred Hutchinson Cancer Research Center, University of Washington Seattle WA
1995, Clinical Fellow, Bone Marrow Transplantation, Solid Tumor and Lymphoma Autologous Marrow Program Dana Farber Cancer Institute and Beth Israel Hospital, Boston, MA
1991 - 1993, Strong Memorial Hospital University of Rochester, Rochester, NY
2022-present, Executive Medical Director, Hematology, City of Hope Orange County
2021-present, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2015-present, Director, Judy and Bernard Briskin Center for Myeloma, City of Hope, Duarte, CA
2004-2018, Associate Director, Medical Education and Training, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
1997-present, Staff Physician, Department of Hematology and Hematopoietic Cell Transplantation City of Hope
-
A Chari, M.D., MC. Minnema, M.D., JG. Berdeja, M.D., A Oriol, M.D., Ph.D., N van de Donk, M.D., Ph.D., P Rodríguez-Otero, M.D., Ph.D., E Askari, M.D., M Mateos, M.D., Ph.D., LJ. Costa, M.D., Ph.D., JCaers, M.D., Ph.D., R Verona, Ph.D., S Girgis, Ph.D., S Yang, Ph.D., RB. Goldsmith, Ph.D., X Yao, Ph.D., K Pillarisetti, M.Sc., BW. Hilder, Ph.D., J Russell, M.D., Ph.D., JD. Goldberg, M.D., and A Krishnan, M.D. “Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.” N Engl J Med 2022; 387:2232-2244, DOI: 10.1056/NEJMoa2204591. December 15, 2022
-
P. Moreau, A.L. Garfall, N.W.C.J. van de Donk, H. Nahi, J.F. San-Miguel, A. Oriol, A.K. Nooka, T. Martin, L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M.-V. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez-López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S.X.W. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Van Rampelbergh, A. Banerjee, J.D. Goldberg, R. Kobos, A. Krishnan, and S.Z. Usmani. “Teclistamab in Relapsed or Refractory Multiple Myeloma.” N Engl J Med 2022;387:495-505. DOI: 10.1056/NEJMoa2203478. June 5, 2022
-
Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17. PMID: 30653422
-
A Krishnan, P Sonneveld. Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma? Lancet Haematol. 2020 Jun;7(6):e445-e446. doi: 10.1016/S2352-3026(20)30149-6.PMID: 32470436
- Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2020 Aug 11. Online ahead of print. PMID: 32778736
- Krishnan A, Adhikarla V, Poku EK et al. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020 Oct 27;4(20):5194-5202. doi: 10.1182/bloodadvances.2020002603.PMID: 33095874.